AJG-22-1928 1248..1255
暂无分享,去创建一个
H. Ikeuchi | Takeshi Yamada | R. Seishima | Y. Ajioka | Y. Toiyama | T. Wakai | K. Sugihara | S. Ishihara | E. Sunami | T. Kiyomatsu | Y. Kanemitsu | Seiichiro Yamamoto | D. Shida | Shin-ichi Sasaki | M. Uchino | K. Futami | K. Matsuda | J. Okuda | K. Hida | K. Uehara | A. Maemoto | S. Kazama | K. Okabayashi | J. Hasegawa | R. Nezu | Yasuhito Iseki | T. Noake | Y. Kinugasa | M. Itabashi | K. Katsumata | F. Koyama | Kazutaka Yamada | Kiyoshi Maeda | S. Yamaguchi | T. Hanai | T. Suto | K. Daito | H. Kimura | J. Arakaki | Kenichi P. Takahashi | Masafumi Nakamura | Hiroki Ohge | H. Ueno | T. Noguchi | Yuji Sato | K. Komori | Takenori Goi | T. Ogino | Kazuhiro Watanabe | Kinya Okamoto | F. Ishida | Takayuki Yamamoto | Yoshito Akagi
[1] H. Ikeuchi,et al. Clinical features and oncological outcomes of intestinal cancers associated with ulcerative colitis and Crohn’s disease , 2022, Journal of Gastroenterology.
[2] S. Itzkowitz,et al. Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. , 2021, Gastroenterology.
[3] S. Weissman,et al. Colorectal Cancer Prevention in Inflammatory Bowel Disease: A Systematic Analysis of the Overall Quality of Guideline Recommendations. , 2021, Inflammatory bowel diseases.
[4] F. Hoentjen,et al. Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease: systematic review and meta-analysis. , 2020, Gastroenterology.
[5] S. Pallio,et al. Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literature , 2020, Expert review of anticancer therapy.
[6] G. Ghitulescu,et al. Trends in Colectomies for Colorectal Neoplasms in Ulcerative Colitis: a National Inpatient Sample Database Analysis over Two Decades , 2020, Journal of Gastrointestinal Surgery.
[7] H. Ikeuchi,et al. Changes in the rate of and trends in colectomy for ulcerative colitis during the era of biologics and calcineurin inhibitors based on a Japanese nationwide cohort study , 2019, Surgery Today.
[8] M. Parkes,et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults , 2019, Gut.
[9] J. Feuerstein,et al. Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments , 2019, World journal of gastroenterology.
[10] Y. Nishiwaki,et al. Estimated prevalence of ulcerative colitis and Crohn’s disease in Japan in 2014: an analysis of a nationwide survey , 2019, Journal of Gastroenterology.
[11] J. Feuerstein,et al. Surgery in the age of biologics , 2019, Gastroenterology report.
[12] K. Mikami,et al. Anorectal cancer surveillance in Crohn's disease , 2018, Journal of the anus, rectum and colon.
[13] X. Qiu,et al. Systematic review with meta‐analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease , 2018, Alimentary pharmacology & therapeutics.
[14] Nima Hamidi,et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies , 2017, The Lancet.
[15] A. Hart,et al. Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study , 2017, Gut.
[16] C. Langner,et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. , 2017, Journal of Crohn's & colitis.
[17] P. Lakatos,et al. The epidemiology of inflammatory bowel diseases from West to East , 2017 .
[18] X. Qiu,et al. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis , 2016, Oncotarget.
[19] H. Ikeuchi,et al. Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan , 2016, Surgery Today.
[20] A. O’Connor,et al. Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis , 2015, Inflammatory bowel diseases.
[21] L. Peyrin-Biroulet,et al. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[22] P. Munkholm,et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. , 2014, Journal of the American Medical Association (JAMA).
[23] L. Peyrin-Biroulet,et al. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[24] P. Rutgeerts,et al. A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease , 2012, The American Journal of Gastroenterology.
[25] M. V. van Oijen,et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease , 2011, Gut.
[26] Norbert Senninger,et al. Intestinal Cancer Risk in Crohn’s Disease: A Meta-Analysis , 2011, Journal of Gastrointestinal Surgery.
[27] J. Avorn,et al. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. , 2010, American journal of epidemiology.
[28] A. Kornbluth,et al. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.
[29] A. Sapino,et al. Azathioprine, mucosal healing in ulcerative colitis, and the chemoprevention of colitic cancer: a clinical-practice-based forecast. , 2010, Inflammation & allergy drug targets.
[30] A. Darzi,et al. The Risk of Cancer in Patients with Crohn’s Disease , 2007, Diseases of the colon and rectum.
[31] I. Buchan,et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.
[32] M. F. William A. Bye B. Com,et al. Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis , 2018, The American Journal of Gastroenterology.
[33] S. Ng,et al. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. , 2017, Gastroenterology.